Pharmacologic management of portal hypertension.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Liver Disease

• Publication date

  2014-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cld.2013.12.003PMID 24679496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

  2014cited by this paper
• Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence

  2013cited by this paper
• Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.

  2013cited by this paper
• Impact of obesity and insulin-resistance on cirrhosis and portal hypertension.

  2013cited by this paper
• Carvedilol: the β-blocker of choice for portal hypertension?

  2013cited by this paper
• Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.

  2013cited by this paper
• Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis.

  2013cited by this paper
• Terutroban, a TP‐receptor antagonist, reduces portal pressure in cirrhotic rats

  2013cited by this paper
• Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis

  2013cited by this paper
• PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.

  2012cited by this paper
• Acute Variceal Bleeding

  2012cited by this paper
• Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol

  2012cited by this paper
• Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding

  2012cited by this paper
• Functional aspects on the pathophysiology of portal hypertension in cirrhosis.

  2012cited by this paper
• Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial.

  2012cited by this paper
• The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study

  2012cited by this paper
• New therapeutic paradigm for patients with cirrhosis

  2012cited by this paper
• Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.

  2011cited by this paper
• Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib

  2011cited by this paper
• Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis

  2011cited by this paper
• 107 EFFECTS OF SIMVASTATIN ADMINISTRATION ON LIVER MICROVASCULAR DYSFUNCTION INDUCED BY LPS

  2011cited by this paper
• Hepatorenal syndrome, pharmacological therapy, and liver transplantation

  2011cited by this paper
• Current status of novel antifibrotic therapies in patients with chronic liver disease

  2011cited by this paper
• DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY Carvedilol for Portal Hypertension in Patients with Cirrhosis

  2010cited by this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cited by this paper
• Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension

  2010cited by this paper
• Management of varices and variceal hemorrhage in cirrhosis.

  2010cited by this paper
• Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis.

  2010cited by this paper
• Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.

  2010cited by this paper
• Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.

  2009cited by this paper
• Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

  2009cited by this paper
• Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis

  2009cited by this paper
• Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration.

  2009cited by this paper
• Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis

  2009cited by this paper
• Angiogenesis in liver disease.

  2009cited by this paper
• Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed

  2009cited by this paper
• The clinical use of HVPG measurements in chronic liver disease

  2009cited by this paper
• Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.

  2008cited by this paper
• A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

  2008cited by this paper
• Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension

  2008cited by this paper
• Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

  2008cited by this paper
• Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats.

  2007cited by this paper
• Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho‐kinase and activation of endothelial nitric oxide synthase

  2007cited by this paper
• Vascular deterioration in cirrhosis: the big picture.

  2007cited by this paper
• Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability

  2007cited by this paper
• Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension

  2006cited by this paper
• Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review.

  2006cited by this paper
• The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis

  2006cited by this paper
• LIVER FAILURE AND LIVER DISEASE

  2005cited by this paper
• Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

  2005cited by this paper
• Acute Hemodynamic Effects of Octreotide and Terlipressin in Patients with Cirrhosis: A Randomized Comparison

  2005cited by this paper
• Hemodynamic Effects of Terlipressin and High Somatostatin Dose during Acute Variceal Bleeding in Nonresponders to the Usual Somatostatin Dose

  2005cited by this paper
• Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis

  2005cited by this paper
• Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.

  2004cited by this paper
• Pharmacological rationale for the use of somatostatin and analogues in portal hypertension

  2003cited by this paper
• Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers.

  2003cited by this paper
• Prevention of variceal rebleeding.

  2003cited by this paper
• Terlipressin in acute oesophageal variceal haemorrhage

  2003cited by this paper
• Randomized comparison of long‐term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis

  2002cited by this paper
• Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial.

  2002cited by this paper
• Somatostatin and analogues in portal hypertension

  2002cited by this paper
• “A la carte” treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding

  2002cited by this paper
• Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding.

  2001cited by this paper
• Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding.

  2001cited by this paper
• Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension.

  2001cited by this paper
• Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study

  2000cited by this paper
• Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients.

  2000cited by this paper
• 48-Hour Hemodynamic Effects of Octreotide on Postprandial Splanchnic Hyperemia in Patients with Liver Cirrhosis and Portal Hypertension

  2000cited by this paper
• Carvedilol, a new nonselective beta‐blocker with intrinsic anti‐alpha1‐adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis

  1999cited by this paper
• Time profile of the haemodynamic effects of terlipressin in portal hypertension.

  1997cited by this paper
• Platelet cytosolic calcium concentration in patients with liver cirrhosis. Relationship with hepatic and systemic hemodynamics.

  1997cited by this paper
• Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.

  1996cited by this paper
• Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function.

  1995cited by this paper
• Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double‐blind hemodynamic investigation

  1995cited by this paper
• Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension.

  1994cited by this paper
• Hemodynamic effects of α‐adrenergic blockade with prazosin in cirrhotic patients with portal hypertension

  1994cited by this paper
• Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension.

  1994cited by this paper
• The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis.

  1994cited by this paper
• Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension.

  1990cited by this paper
• Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function.

  1989cited by this paper
• Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis

  1988cited by this paper
• Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients.

  1981cited by this paper
• Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.

  1981cited by this paper
• Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study.

  1981cited by this paper
• Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin

  1981cited by this paper
• Propranolol--a medical treatment for portal hypertension?

  1980cited by this paper
• Letter: Sprue again.

  1975cited by this paper
• CHRONIC ILLNESS IN YOUNG PEOPLE.

  1964cited by this paper

• Cardiac Remodeling and Arrhythmic Burden in Pre-Transplant Cirrhotic Patients: Pathophysiological Mechanisms and Management Strategies

  2025cites this paper
• Pharmacologic Treatment of Portal Hypertension.

  2024cites this paper
• Study of Propranolol in Cirrhosis Patients with Portal Hypertension: Research at Sidoarjo General Hospital

  2023cites this paper
• Close Relationship between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver

  2023cites this paper
• ПОРТАЛДЫҚ ГИПЕРТЕНЗИЯ (ӘДЕБИ ШОЛУ)

  2023cites this paper
• Symptomatic Hyponatremia in a Patient With Hepatorenal Syndrome Treated with Terlipressin.

  2022cites this paper
• Investigational drugs in early clinical development for portal hypertension

  2022cites this paper
• Management of Patients With Gastric Varices.

  2022cites this paper
• Successful Percutaneous Transhepatic Obliteration Plus Sengstaken-Blakemore Tube Combination Therapy for Recurrent Gastroesophageal Variceal Bleeding

  2022cites this paper
• The role of microRNAs on the pathogenesis, diagnosis and management of portal hypertension in patients with chronic liver disease

  2022cites this paper
• Comparison of portal hypertensive gastropathy and gastric antral vascular ectasia: an update

  2022cites this paper
• The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study

  2021cites this paper
• Efficacy and Safety of Treatments for Patients With Portal Hypertension and Cirrhosis: A Systematic Review and Bayesian Network Meta-Analysis

  2021cites this paper
• Hepatocrinology

  2021cites this paper
• Simultaneous evaluation of perfusion and morphology using GRASP MRI in hepatic fibrosis

  2021cites this paper
• Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis.

  2021cites this paper
• The Space of Disse: The Liver Hub in Health and Disease

  2021cites this paper
• Drug Discovery in Liver Disease Using Kinome Profiling

  2021cites this paper
• Novel therapeutics for portal hypertension and fibrosis in chronic liver disease.

  2020cites this paper
• Some aspects related to the human body plant

  2020cites this paper
• Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical

  2020cites this paper
• Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension

  2020cites this paper
• Noninvasive imaging assessment of portal hypertension

  2020cites this paper
• Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature

  2020cites this paper
• Beta-blockers and Statins: Role in Portal Hypertension and Beyond

  2020cites this paper
• Future Prospects in the Treatment of Portal Hypertension

  2019cites this paper
• Non-invasive Measurement of Portal Pressure

  2019cites this paper
• Pharmacologic Management of Portal Hypertension.

  2019cites this paper
• Intensive Care Tactics for Reducing Gastrointestinal Bleeding in the Context of Portal Hypertension

  2019cites this paper
• Тактика интенсивной терапии при желудочно-кишечных кровотечениях на фоне портальной гипертензии

  2019cites this paper
• Intensive Care Tactics for Reducing Gastrointestinal Bleeding in the Context of Portal Hypertension

  2019cites this paper
• Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives

  2018cites this paper
• Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials

  2018cites this paper
• Portal Hypertension in Cirrhosis

  2018cites this paper
• Hepatic microcirculation and mechanisms of portal hypertension

  2018cites this paper
• Перспективы антиангиогенной терапии портальной гипертензии при циррозе печени

  2018cites this paper
• Pulmonary hypertension associated with portal hypertension and pulmonary hypertension in sarcoididosis of breathing organs: complex pathogenetic relationships

  2018cites this paper
• Prospects of Antiangiogenic Therapy for Portal Hypertension in Liver Cirrhosis

  2018cites this paper
• Hypothalamic and inflammatory basis of hypertension.

  2017cites this paper
• Prevention and treatment of variceal haemorrhage in 2017

  2017cites this paper
• The Principles of primary prophylaxis of bleeding from oesophagealvaricies in patients with liver cirrhosis.

  2016cites this paper
• Emerging therapies for portal hypertension in cirrhosis

  2016cites this paper
• [Aspects of pathogenetc pharmacotherapy for portal hypertension in liver cirrhosis].

  2016cites this paper
• Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension.

  2016cites this paper
• Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

  2015cites this paper
• CIRRHOTIC PORTAL HYPERTENSION: NEW INSIGHTS IN AN OLD SYNDROME

  2015cites this paper
• Hyponatraemia induced by terlipressin: a case report and literature review

  2015cites this paper
• Portal hypertensive gastropathy with a focus on management

  2015cites this paper
• Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.

  2015cites this paper
• Nonendoscopic management strategies for acute esophagogastric variceal bleeding.

  2014cites this paper
• Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension

  2014cites this paper
• Gastric bypass surgery in NASH: a major modulator of hepatic mitochondrial dysfunction

  2014cites this paper